RVNC241220C2500
- 1.63
- 0.000.00%
Revance Therapeutics Newsroom
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Barclays Remains a Hold on Revance Therapeutics (RVNC)
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Cautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties With Crown Laboratories
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Revance Therapeutics Jumps After Crown Laboratories Tender Offer Extended Again
Stifel Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $6.66
Revance Therapeutics Analyst Ratings
H.C. Wainwright Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $6.6
Revance Therapeutics Faces Strategic Uncertainty Amid Financial Shortfalls and Acquisition Challenges
Revance Therapeutics (RVNC) Gets a Hold From Needham
12 Health Care Stocks Moving In Friday's Pre-Market Session
Revance Therapeutics Reports Q3 Growth Amid Merger Plans
Revance Therapeutics Sinks Amid `going Concern' Disclosure
Express News | Revance Therapeutics: Will Not Be Providing Any Forward-Looking Guidance & Withdrawing Previously Provided Guidance & Outlook
Revance Therapeutics Q3 EPS $(0.37) Beats $(0.38) Estimate, Sales $59.88M Miss $68.20M Estimate
Revance Therapeutics | 10-Q: Q3 2024 Earnings Report
Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q3 Revenue $59.9M
Revance Therapeutics | 8-K: Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update
Express News | Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update